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ABSTRACT 
Homocysteine (Hcy) is an intermediate of methionine metabolism and acts 
as a critical branch point between protein synthesis and numerous regulatory 
pathways in the cell.  Elevated plasma total Hcy (tHcy) is associated with an 
increased risk for cardiovascular disease, although the mechanism by which this 
occurs remains unclear.  Two enzymes are responsible for the remethylation of 
Hcy to methionine: methionine synthase and betaine-homocysteine 
methyltransferase (BHMT).  Methionine synthase function depends on adequate 
availability of vitamin B12 and folate which links cardiovascular disease risk to 
nutritional status.  The Hcy remethylation pathway through BHMT, however, 
requires only the substrate betaine which is derived from dietary or synthesized 
choline.  Recently, unpublished crystallography pictures have shown a potassium 
ion that is interacting with some of the residues of BHMT that are involved in 
Hcy- and betaine-binding.  These residues include Asp26 and Gly27, which 
along with Gly28 comprise an amino acid fingerprint that is common among Hcy 
S-methyltransferase proteins.  All three residues of this DGG motif were 
substituted with a different amino acid (Asp26Ala, Gly27Ser and Gly28Ser) to 
examine the effect these residues have on BHMT activity, potassium-binding and 
substrate-binding kinetics.  We demonstrate that these substitutions are directly 
responsible for decreases in Hcy binding, enzyme velocity and catalytic turnover.  
Mutations in the potassium coordination sphere appear to be more detrimental to 
BHMT function than changes to the other conserved residue.   
 
 iii 
ACKNOWLEDGEMENTS 
 
This project would not have been possible without the support and 
direction of many people.  I would like to thank my advisor, Dr. Timothy Garrow, 
for taking in a young, inexperienced undergraduate student and teaching her the 
skills to become a capable scientist.  I will carry with me the many lessons 
learned under your supervision throughout my career.  Your friendship and 
guidance throughout these years will not be soon forgotten.  I would also like to 
thank his wife, Linda Garrow, for giving me the opportunity to learn from her while 
teaching together at the University of Illinois. 
 Thank you to Carrie Diamond for starting this project in the Garrow lab 
and showing me the ropes of protein purification.  Carrie performed the 
mutagenesis of the proteins but was unable to continue the project and so the 
project became mine alone.  Thanks to my committee members, Dr. Manabu 
Nakamura, Dr. Yuan-Xiang Pan and Dr. Michael Miller, for their insight and 
encouragement throughout the whole process.  I would also like to thank Markos 
Koutmos for sharing his unpublished crystallography pictures that became the 
foundation of my project. 
 Most importantly, I would like to thank my parents, Lyle and Vicki, for their 
unwavering encouragement and understanding during my time here.  You alone 
are the reason my dream of an education was made possible.  Your 
unconditional love and hope for a better future are the reasons I was able to 
survive it all.  And finally, thank you to my sister, Sarah, for keeping me sane 
during crazy times, for being my confidant and for always being my friend. 
 iv 
TABLE OF CONTENTS 
 
CHAPTER 1: INTRODUCTION AND BACKGROUND....................................... 1 
 Sulfur Amino Acid Metabolism................................................................. 1 
 Homocysteine Metabolism: Relationship to Human Disease.................. 6 
 Betaine-Homocysteine Methyltransferase............................................... 12 
CHAPTER 2: THE ROLE OF POTASSIUM IN BHMT....................................... 18 
 Introduction.............................................................................................. 18 
 Materials and Methods............................................................................ 20 
 Results and Discussion........................................................................... 27 
 Conclusion...............................................................................................  38 
REFERENCES...................................................................................................  40 
 
 
 
 
 
 
 
 1 
Chapter 1: Introduction and Background 
 
Sulfur Amino Acid Metabolism 
 
 Proteins are composed of twenty common amino acids of which only two 
contain the element sulfur: methionine (Met) and cysteine.  Homocysteine (Hcy) 
is a four carbon, sulfur-containing amino acid that is not found in proteins but is 
formed as an intermediate of Met metabolism.  Humans are incapable of 
synthesizing the carbon skeleton of Hcy, rendering Met nutritionally essential for 
maintenance and growth.  Other amino acids required in the human diet include 
histidine, phenylalanine, isoleucine, leucine, threonine, valine, lysine and 
tryptophan. Cysteine can be synthesized de novo by using the sulfur atom of 
Met, which is found mostly in animal food sources such as meat and eggs, and 
the carbon skeleton of serine.  Therefore, a requirement for cysteine is not 
essential as long as a diet provides adequate levels of Met. 
 Hcy is an important intermediate between the biosynthesis of cysteine, the 
regeneration of Met and the production of S-adenosylmethionine (SAM), a critical 
substrate and regulatory molecule of metabolism.  Hcy lies at a metabolic branch 
point in sulfur amino acid metabolism and has two possible fates in the human 
body (Fig 1).  One potential outcome for Hcy is to go through the two-step 
transsulfuration pathway that results in the biosynthesis of cysteine.  The other 
outcome involves the remethylation of Hcy to regenerate Met.  This remethylation 
can be catalyzed by two different mammalian enzymes: the folate- and B12-
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dependent methionine synthase or betaine-homocysteine methyltransferase 
(BHMT), the latter of which uses betaine (N,N,N-trimethylglycine) as the methyl 
donor substrate.   
 
Methionine Cycle 
  
Met is a metabolite found in several pathways and a significant portion of 
the Met consumed in the diet is utilized quickly to sustain protein synthesis.  
Plasma Met levels are kept very low with excess removed from circulation by the 
liver.  Most Met is converted to SAM by the enzyme methionine 
adenosyltransferase.  SAM is required for the methylation of many different 
biological molecules including DNA, RNA, phospholipids and proteins.  SAM can 
be demethylated through transmethylation reactions catalyzed by several 
enzymes to form S-adenosylhomocysteine.  S-adenosylhomocysteine is then 
hydrolyzed by S-adenosylhomocysteine hydrolase to produce Hcy, adenosine 
and water.  Hcy can then be remethylated to form Met through the BHMT or 
methionine synthase reactions or it can go through the reactions that result in the 
degradation of Hcy and the biosynthesis of cysteine.  The regulation of the Met 
metabolic pathway occurs based on the availability of Met and cysteine.  If both 
of these amino acids are in adequate quantities, elevated SAM levels 
allosterically activate cystathionine β-synthase, involved in Hcy degradation to 
cystathionine, and inhibit methylenetetrahydrofolate reductase (MTHFR), pushing 
Hcy toward degradation.  If Met levels are less than adequate, SAM levels are 
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decreased which lifts the inhibition of MTHFR and reduces cystathionine β-
synthase activation, pushing Hcy toward remethylation. 
 Both methionine synthase and BHMT are able to remethylate Hcy but 
have different regulatory factors and expression locations.  Methionine synthase 
is a cytosolic, monomeric protein that is expressed in all mammalian cells, with 
the exception of the intestinal mucosa1,2,3,4.  Methionine synthase synthesizes 
Met S-methyl groups using one-carbon units derived from 5’-N’-
methyltetrahydrofolate (MTHF).  Requiring vitamin B12 as a coenzyme, 
methionine synthase binds the methyl group of MTHF to colbalamin until it is 
transferred to Hcy to form Met5.  MTHF is required for methionine synthase 
activity and is produced as an intermediate of the folate cycle.  First, 
tetrahydrofolate is converted to methylene tetrahydrofolate through a reaction 
catalyzed by the vitamin B6-dependent serine hydroxymethyltransferase and 
second, methylene tetrahydrofolate is reduced by MTHFR to yield MTHF.  
Therefore, methionine synthase function is completely reliant on the availability of 
folic acid, vitamin B6 and vitamin B12 in the cell.  
Although the role of methionine synthase in Hcy homeostasis has been 
the focus of much research, more recent insights suggest that the liver accounts 
for 85% of transmethylation reactions and up to 50% of Hcy remethylation in liver 
happens through BHMT6, 7.  BHMT is a cytosolic enzyme found almost 
exclusively in the liver and kidney8.  In these tissues, BHMT catalyzes a methyl 
transfer from a choline-derived donor, betaine, to Hcy.  This reaction produces 
Met, as well as dimethylglycine (DMG)8.  Unlike methionine synthase, BHMT 
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 is not dependent on B-vitamins and its substrate betaine can be found 
abundantly in the diet9,10 or produced as an intermediate of choline oxidation.   
Dietary choline is oxidized only in the liver and kidney through an 
irreversible set of reactions.  Free choline is taken into the mitochondria where it 
is first oxidized by choline oxidase to produce betaine aldehyde.  During the next 
reaction, betaine aldehyde becomes betaine via oxidation by betaine aldehyde 
dehydrogenase.  Because betaine cannot be reduced to form choline, it is 
transported into the cytosol to serve as a substrate for BHMT which results in the 
production of DMG.  DMG is then transported back to the mitochondria where it 
is converted to sarcosine by DMG dehydrogenase.  Sarcosine, a natural amino 
acid found in muscles and other body tissues, is rapidly degraded to glycine by 
sarcosine dehydrogenase.  Besides being a precursor to proteins, glycine also 
goes through the glycine cleavage system which forms methylene 
tetrahydrofolate and provides another pathway for the biosynthesis of one-carbon 
units. 
 
Transsulfuration 
 
 The other outcome of Hcy metabolism, as previously stated, is the 
biosynthesis of cysteine through the transsulfuration pathway.  This pathway is 
found exclusively in the liver, kidney, small intestine and pancreas11 and occurs 
during times of Met excess to remove Hcy from the remethylation cycle.  Through 
two reactions, the sulfur atom of Hcy is transferred to serine to form cysteine.  
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The first step involves an irreversible condensation of Hcy with serine to form 
cystationine by the vitamin B6-dependent cystathionine β-synthase.  The enzyme 
cystathionine lyase then cleaves cystathionine, forming α-ketobutyrate, ammonia 
and cysteine.  Glutathione, another critical metabolite, is also synthesized from 
cysteine.  Cysteine and L-glutamate are condensed by glutamate cysteine ligase 
to form gamma-glutamylcysteine.  Glycine is then added to the C-terminal end of 
gamma-glutamylcysteine by glutathione synthetase forming glutathione.  This 
tripeptide is the major endogenous antioxidant produced by cells and plays a 
fundamental role in numerous metabolic and chemical reactions such as DNA 
synthesis and repair, protein synthesis, prostaglandin synthesis and 
detoxification of many carcinogens and drugs from the body.  The physiological 
demand in the liver for glutathione’s antioxidant properties may shift Hcy away 
from remethylation to transsulfuration. 
 
 
Homocysteine Metabolism: Relationship to Human Disease 
 
 Cardiovascular disease has managed to hold steady as the most common 
cause of death for men and women in the United States12.  Cardiovascular 
disease affects millions of people worldwide and is often a chronic condition that 
can decrease the quality of life for many years.  Due to the prevalence of this 
disease, much research has been conducted to investigate the exact etiology of 
heart and vascular diseases.  Nutrition and lifestyle choices can have a large 
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effect on many identified risk factors that can result in the premature 
development of atherosclerosis.  These independent risk factors include obesity, 
central adiposity, hyperlipidemia, hypertension and chronic inflammation.  One of 
the more recently identified and poorly understood independent risk factors for 
the development of all forms of cardiovascular disease regardless of the 
underlying cause is hyperhomocysteinemia (HHcy), or elevated levels of plasma 
total homocysteine (tHcy).   
The association between elevated tHcy and the development of 
atherosclerosis was first established when researchers observed that individuals 
with defective cystathionine β-synthase or cobalamin genes had severe 
premature thrombovascular disease and elevated tHcy was the only common 
metabolic disturbance13.  Soon after, an abnormality in the MTHFR gene 
hindering its ability to convert methylene tetrahydrofolate to MTHF, a substrate 
used by methionine synthase, was also linked to HHcy and atherosclerosis14.  
 
Nutrition and Genetic Factors Influencing Plasma Homocysteine  
 
 Numerous nutritional and genetic conditions are known to give rise to 
elevated tHcy and HHcy.  Because HHcy is a risk factor for cardiovascular 
disease regardless of any underlying cause, it is important to know the rate of 
incidence and populations most at risk.  At a relatively high frequency, 
homozygous mutations for severe HHcy are estimated to be between 1 in 35,000 
and 1 in 100,000 live births15.  In the United States, estimates suggest that 
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heterozygosity for homocystinuria occurs as often as 1 in 200 or 1 in 300 live 
births16.  Phenylketonuria is the only genetic disorder in amino acid metabolism 
that is more prevalent.  Since studies have shown that defects in cystathionine β-
synthase and MTHFR, which is required for methionine synthase to function 
normally, lead to elevated tHcy and vascular disease, populations who are 
heterozygous or homozygous for mutations in cystathionine β-synthase, MTHFR 
or methionine synthase are considered at risk for HHcy. 
 As stated previously, many reactions involved in the remethylation and 
transsulfuration of Hcy are vitamin-dependent.  Therefore, nutritional status is 
important in determining an individual’s risk for HHcy.  One study showed that 
lowered intake of vitamins B6, B12 and folate in the elderly correlated to an 
elevation in tHcy17, while another study demonstrated that women who had the 
lowest intakes of B6 and folate also had the greatest risk for myocardial 
infarction18.  Often times, optimal intake of the micronutrients involved in Hcy 
metabolism (vitamin B6, vitamin B12, folate and betaine) can effectively lower 
tHcy levels that are elevated due to genetic problems with enzymes in the folate 
cycle and transsulfuration pathway.  The forms of homocystinuria that are non-
responsive to vitamin therapy alone have been shown to respond to large oral 
doses of betaine, which effectively lower tHcy19,20.  Under most dietary 
conditions, BHMT is not saturated with its substrate betaine in the liver and 
increased levels of liver betaine leads to increased methylation of Hcy by the 
BHMT-catalyzed reaction.  This provides the explanation for the tHcy-lowering 
effect of betaine treatment.  It has been shown that rodents fed a diet relatively 
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low in Met and devoid of choline, such as a soybean protein diet, causes 
prominent HHcy which can be suppressed by betaine supplementation21.  
Supplemental betaine has also been shown to relieve neurological defects,  
HHcy and hepatic steatosis in cystathionine β-synthase and MTHFR deficient 
rodents, demonstrating the importance of the BHMT remethylation 
pathway22,23,24.   
 Populations at risk for Hcy-induced vascular disease are those with 
mutations in genes that play a role in Hcy metabolism or have poor nutritional 
status.  Acute exercise also appears to elevate tHcy levels post-activity, although 
the mechanism for this is poorly understood25.  This increase occurs 
independently of the type of exercise, amino acid metabolic stress or vitamin 
status, suggesting a possible connection to changes in renal function during 
activity25.  Overall, it is clear those individuals with HHcy or who are at risk for 
HHcy should intake a diet with increased levels of folic acid, vitamin B6 and 
vitamin B12.  Lowering tHcy levels in homocystinurics can prevent many possible 
dangerous side effects, including thrombosis and death. 
 
Effects of Hyperhomocysteinemia 
 
 The mechanism by which elevated tHcy increases the risk for 
cardiovascular disease is not completely understood but recent research has 
uncovered several metabolic changes that occur during HHcy and their 
relationship to the disease.  In rodents, HHcy clearly induces arterial endothelial 
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injury by decreasing levels of endothelin-coverting enzymes26.  Injury to the 
arterial lining dramatically contributes to several types of cardiovascular disease, 
including ischemic heart disease, stroke and peripheral vascular disease.  
Oxidative stress caused by HHcy appears to play another crucial role in 
relationship to vascular damage.  One study shows that elevated tHcy activates 
mononuclear cells which induces oxidative stress and leads to increased 
endothelial dysfunction, lipid peroxidation and production of inflammatory factors 
which are critical to Hcy-induced vascular damage and atherosclerosis27.  
Rodents with HHcy also show the presence of inflammatory infiltrate and fibrosis 
in the liver, as well as an overall decrease in antioxidant defenses and total thiol 
content, indicating oxidative stress and liver injury28.  Since inflammation and 
oxidative stress appear to be critical to HHcy-induced cardiovascular disease, 
anti-inflammatory and antioxidative drugs could serve as therapeutic strategies in 
the future27.   
Besides endothelial dysfunction, other negative effects of elevated tHcy 
have been shown to occur in many areas of the body, including the liver, bone 
and the brain.  Cystathionine β-synthase-deficient mice show a significant 
decrease in activity of liver thiolase, a key enzyme in β-oxidation of fatty acids, 
and subsequently show an increase in triglyceride and nonesterified fatty acid 
levels in liver and serum29.  This abnormal lipid metabolism was associated with 
hepatic steatosis in the mice29 and hyperlipidemia is already known to be a very 
strong risk factor for cardiovascular disease.  Cystathionine β-synthase-deficient 
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mice also tend to suffer from facial alopecia, osteoporosis and have an overall 
20% reduction in mean survival time30.   
The prevalence of osteoporosis in the presence of elevated tHcy has lead 
to studies focused on the relationship between HHcy and bone.  Rodents with 
HHcy show a tissue specific accumulation of Hcy in bone with 65% of this Hcy 
bound to the collagen of the extracellular matrix31.  This bound Hcy has the 
potential to weaken collagen cross links and cause problems with bone 
remodeling.  This accumulation of Hcy in bone also leads to a significant 
decrease in the amount of cancellous bone and overall bone strength31.  These 
effects are seen in humans as well.  Using a group of postmenopausal women, 
researchers were able to link plasma Hcy with osteoporosis32 and conclude that 
HHcy decreases the quality of bone enough to consider it a causal osteoporotic 
factor33.  HHcy also appears to have an effect on the body’s most important 
organ, the brain.  The oxidative stress caused by HHcy has a large effect on 
neurotoxicity and the increased Hcy to Met ratio leads to a decrease in SAM 
activity and impaired metabolism of neurotransmitters34.  This can lead to the 
development of various disorders, including depression.   
Overall, elevated tHcy has a clear impact on many different metabolic 
processes.  It is important that research continues to explore all the effects that 
HHcy has in association with human disease.  It is also important to look carefully 
at the metabolic pathways in which plasma Hcy levels are lowered and to gather 
knowledge of the enzymes involved in these processes. 
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Betaine-Homocysteine Methyltransferase 
 
Physical Characteristics 
 
BHMT is a cytosolic enzyme that catalyzes the transfer of a methyl group 
from betaine to Hcy, forming DMG and Met.  BHMT is a tetramer made up of 
identical 45 kilodalton (kD) monomers and has been detected in both 
prokaryotes, such as P. denitrificans and Aphanothece halophytica, and 
eukaryotes8,35,36.  The alternative enzyme to remethylate Hcy, methionine 
synthase, requires vitamin cofactors, is expressed at a continuous low level 
throughout most tissues and has a high turnover rate (Kcat)2.  In contrast, BHMT 
has a very low turnover rate (Kcat) and is expressed at high levels in the liver and 
kidney.  In humans, the liver is responsible for processing 48% of dietary 
methionine37 and has been suggested as the main organ in charge of regulating 
tHcy38.  BHMT in the liver of most species accounts for 0.6-1.6% of the total 
protein8,39,40 and the remethylation reaction it catalyzes processes 25% of the 
cellular Hcy in a rat liver model7.  Although the kidney is another location of 
BHMT expression, its activity there is found to be lower for humans, pigs and 
rats8,41.  Betaine, a substrate of BHMT, has an important role as a cellular 
osmolyte to help regulate cellular volume42 and is produced in the renal cortex, 
the area of the kidney where BHMT expression is most concentrated in humans 
and pigs43.  Therefore, it seems BHMT has the potential to greatly affect betaine 
levels and the regulation of cellular volume.  Overall, the levels of expression and 
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activity in hepatic and renal tissues strongly suggest that BHMT is a major player 
in Met metabolism and possibly other important roles. 
BHMT is a zinc-dependent thiol/selenol methyltransferase that, in 
mammals, has been highly conserved over time.  BHMT proteins from humans 
and pigs are 88% identical at the nucleotide level and 94% at the amino acid 
level39.  Critical sites on the enzyme include both a betaine- and Hcy-binding 
domain, as well as a site that binds a catalytic zinc molecule.  BHMT also 
contains three C-terminal structural domains that are important to its quaternary 
structure: the dimerization arm; the hook region; and the terminal alpha-helix.  
Any form of BHMT that lacks these domains is unstable in vitro44.  In order to fully 
understand BHMT structure and catalysis, it is necessary to look at each of these 
sites with more detail. 
The betaine- and Hcy-binding domains of BHMT are found in the N-
terminal region.  Homologous to prokaryotic and eukaryotic methionine synthase, 
the Hcy-binding domain of BHMT contains three cysteine thiolates (Cys217, 
Cys299 and Cys300) that bind the catalytic zinc to activate Hcy.  Mutations in 
these three cysteine residues result in low zinc content and no enzymatic 
activity45.  A fourth ligand for zinc has also been identified as a tyrosine residue 
(Tyr160)46.  BHMT follows an ordered bi-bi mechanism of catalysis with Hcy 
being the first substrate to be bound.  Hcy bound at the active site causes a 
structural change in the enzyme and creates the betaine-binding site.  Following 
catalysis, DMG is the first product to leave, followed by Met47.   
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Crystallography of human and rat liver BHMT proteins show the main 
component of monomer folding to be a (β/α)8 barrel formed by residues 11-31848.  
Two important features of the (β/α)8 barrel include the L1 loop of residues 38-52 
that plays an important role in substrate binding and the L7 loop that interacts 
with residues beyond 318 of the opposite monomer.  This interaction holds the 
two monomers together and is known as the dimerization arm.  As part of the 
dimerization arm, a hook-shaped loop composed of residues 362-365 wraps 
around the equivalent loop of the other monomer and forms the hook region that 
allows for interaction with another dimer to form a tetramer.  To add to tetramer 
stabilization, the C-terminal end of BHMT, residues 381-407, forms an alpha-
helix that extends from one monomer to the opposite providing interactions to 
bind the dimers and keep the protein tightly packed46.   
The (β/α)8 barrel structure of BHMT contains distortions that are caused 
by interactions and conformations of residue sequences that are conserved 
amongst the Hcy S-methyltransferase family46.  The three cysteine residues that 
are responsible for binding zinc are located at the ends of strands β6 and β8 of 
the (β/α)8 barrel.  These two strands pinch together in order to fit the zinc site, 
while near the Hcy-binding site, strands β1 and β2 flare apart and open a cleft.  
The source of this cleft is a negative interaction between an aspartic acid residue 
(Asp26) and a glutamine residue (Gln72) from strand β2.  The flaring of these 
two strands provides a large opening for Hcy binding.  An Asp residue at the 
postion equivalent to Asp26 is conserved throughout all Hcy S-methyltransferase 
proteins and is followed by two glycine residues (Gly27 and Gly28) in human 
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BHMT45,48.  These small residues at 27 and 28 allow strand β1 to approach 
strand β8 which permits access of the Hcy carboxylate group to the active site of 
BHMT.   
 
Kinetics and Regulation of Activity 
 
 Many techniques have been developed to quantify BHMT activity, 
substrate binding and regulation.  Kinetic characterization of human BHMT found 
Km values for betaine and L-Hcy to be 100 and 120 µM, respectively39,49.  Since 
betaine treatment in homocystinuria patients is able to lower tHcy levels, it is 
assumed that BHMT is not normally saturated with betaine in human liver.  
Intrinsic fluorescence is used to visualize substrate binding to BHMT by 
measuring amplitude and wavelength of aromatic residue emissions when 
excited by ultraviolet light.  These surface tryptophan residues shift when the 
enzyme binds substrate, causing emission spectra changes, and allow for the 
quantification of binding curves and dissociation constants for each substrate.  
For the enzyme BHMT, the Kd for betaine under saturating concentrations of L-
Hcy is 1.1 µM while the Kd for Hcy under increasing concentrations of L-Hcy was 
found to be 7.9 µM47.  Intrinsic tryptophan fluorescence is used in the research 
reported here to monitor ligand affinity. 
 BHMT is strongly inhibited by its end product, DMG, which competes with 
betaine for the betaine-binding site47.  Dietary Met levels are also able to regulate 
BHMT at the mRNA level.  Adequate or supplemental betaine combined with Met 
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deficiency significantly increases BHMT mRNA and activity levels in rat and chick 
livers50,51.  However, excess dietary Met is also able to upregulate BHMT.  An 
increase in hepatic BHMT activity is observed in rats fed a Met-excessive diet 
coupled with adequate choline52.  A dietary Met load results in transcient HHcy 
as the liver’s capacity to use SAM and degrade Hcy becomes overwhelmed.  
Plasma betaine levels in humans have a direct correlation with the severity of 
post-load tHcy53,54, indicating that BHMT may be more important than methionine 
synthase for managing post-load HHcy.   
As previously mentioned, BHMT has an absolute requirement for zinc for 
enzyme activity.  A reducing agent is also a requirement for catalysis because 
the cysteine residues involved in zinc binding are susceptible to disulfide bond 
formation.  If a disulfide bond is formed between two of the three cysteine 
residues, the enzyme is inactivated even though zinc remains bound to the 
enzyme.  Recently, crystallography has shown that a potassium ion also appears 
to be bound to BHMT (Koutmos et al, unpublished).  Unpublished pictures (Fig 2) 
show interactions between potassium and some of the residues involved in Hcy- 
and betaine-binding.  These residues include Asp26 and Gly27, which along with 
Gly28 comprise an amino acid fingerprint that is common among Hcy S-
methyltransferase proteins.  Although the importance of this cation is unknown, 
the work presented in this thesis shows that mutations in these important 
residues (Asp26Ala, Gly27Ser, and Gly28Ser) result in changes in BHMT 
properties and further research may show a potassium requirement for catalytic 
activity.  
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Chapter 2: The Role of Potassium in BHMT 
 
Introduction 
 
 The discovery of a potassium (K+)-binding site in BHMT found through 
crystallography data of the human enzyme (Koutmos et al, unpublished) has lead 
to many questions regarding the importance of K+ to enzyme activity.  The K+ ion 
appears to interact with the conserved DGG sequence first noted by Breska and 
Garrow45.  As can be seen in Figure 2, two residues of the DGG motif are clearly 
involved in binding K+ to the enzyme and these residues, along with K+, appear 
to be interacting with Hcy.  In this chapter, I describe work designed to determine 
if the K+ ion is required for activity and specifically Hcy-binding.  First, I will 
describe the interaction of K+ with BHMT in more detail.  
 The K+ coordination sphere in BHMT is comprised by the carboxy oxygen 
atom backbones of Gly27, Gly298 and Asp26, as well as the side chain carboxy 
oxygen atoms of Asp26, Gln72 and Gln247.  This coordination sphere is 
completed by two water molecules that are bound to K+ in close proximity to Hcy.  
These water molecules form hydrogen bonds with the carboxy-amido moiety of 
Hcy and therefore link Hcy and K+ through water-mediated interactions.  Beyond 
potential K+  binding, Asp26 and Gly27, along with Gly28, are a highly conserved 
sequence in the Hcy S-methyltransferase family.  This DGG fingerprint is 
involved in the structure of BHMT, helping to make room for Hcy-binding by 
opening a large clef.  Because these residues also appear to be involved in the 
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interaction with K+ , we hypothesize that substitutions of these residues will result 
in decreased K+  binding and changes in BHMT activity, substrate binding and 
initial rate kinetics.  We have designed mutations to evaluate chemical and 
structural properties of these residues.  All three residues of the DGG fingerprint 
have been substitued with either alanine (Asp26) or serine (Gly27 and Gly28). 
 
Alanine  
 
 The substitution of alanine for aspartate at position 26 replaces a strong 
negatively-charged carboxyl group with a small, neutral methyl group.  Although 
aspartate has the capability of stabilizing proteins through hydrogen interactions, 
the side chain of alanine is very non-reactive and is rarely directly involved in 
protein function.  By removing the side chain carboxy oxygen atom of aspartate, 
we hope to disrupt the K+ coordination sphere and interfere with the enzyme’s 
ability to bind K+.  We predict this mutation will cause small, highly localized 
changes in BHMT structure rendering it unable to bind substrate.  We generated 
a single substitution of aspartate to alanine (Asp26Ala). 
 
Serine  
 
 Serine introduces a medium-length, polar side chain in the replacement of 
glycine at residues 27 and 28.  Glycine is nonpolar and the smallest amino acid 
overall with only a hydrogen atom at its side chain used to increase its flexibilty 
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and conformation.  Serine, on the other hand, is larger with a side chain hydroxyl 
oxygen atom that is prone to hydrogen bonding.  A serine at residues 27 and 28 
are two of the most common polymorphisms found in mice and so we chose to 
investigate this substitution more thoroughly at both positions.  We predict adding 
a larger, proton-donating amino acid at these positions will cause disruptions in 
the K+ binding site and reduced substrate binding ability of BHMT. 
 
 
Materials and Methods 
 
Reagents 
 
 Ampicillin, zinc chloride (ZnCl2),  D, L-homocysteine thiolactone, Dowex 
1x4, betaine and D, L-homocystine were obtained from Sigma-Aldrich (St. Louis, 
MO).  Sodium chloride (NaCl), Tris base, ethylenediaminetetraacetic acid 
(EDTA), Triton X100, Tris(2-carboxyethyl)phosphine (TCEP), β-mercaptoethanol 
(βME), urea and bovine serum albumin were obtained from ThermoFisher 
Scientific (Pittsburgh, PA).  Protein assay Coomassie dye reagent concentrate 
and Coomassie Brilliant Blue were obtained from Bio-Rad Laboratories 
(Hercules, CA).  Prokaryotic cell culture media reagents were obtained from 
Becton, Dickenson and Company (Sparks, MA).  All reagents were of the highest 
purity commercially available. 
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Removal of K+ from BHMT  
 
 In attempt to remove K+ by relaxing the enzyme’s structure with urea, 
purified enzyme was dialyzed twice in 1 L of control buffer (50 mM Tris-PO4 pH 
7.5, 100 µM TCEP) containing varying levels of urea (1-3 M) at 4ºC for 6 hours 
each.  The enzyme was then dialyzed against 1 L of a K+- and urea-free control 
buffer at 4ºC for 6 hours.  The dialyzed enzyme was assayed for BHMT activity 
through the standard BHMT activity assay, as mentioned below, with one 
modification.  In order to prevent reintroduction of K+ to the dialyzed enzyme, 
D,L-homocystine was used in lieu of D,L-homocysteine thiolactone and was 
prepared by dissolving 2.68 mg in 250 µl of 500 mM HCl, neutralizing with 400 µl 
of 500 mM Tris base, adding TCEP to a concentration of 50 mM and letting sit at 
room temperature for 30 minutes. 
 
BHMT Purification Vector 
 
 In vitro cloning and expression of human BHMT have been described 
previously (Garrow 1996, Millian et al 1998, Breska and Garrow 1999).  In short, 
a human BHMT cDNA was subcloned into the pTYB4 vector (New England 
Biolabs, Beverly, MA) as part of the IMPACT Protein Purification System.  The 
cDNA is fused at the C-terminus to an intein tag, all of which is downstream of a 
isopropyl-β-D-thiogalactopyranoside (IPTG)-inducible T7 promoter.  The intein-
chitin-binding domain-tagged recombinant BHMT is then able to be purified from 
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bacterial lysates by affinity column chromatography that exploits the strong 
intein-chitin-binding domain affinity. 
 
Mutagenesis in Cloned Human BHMT 
 
 Mutations in human BHMT cDNA (pTYB4::hBHMT) were generated using 
the Strategene (La Jolla, CA) Quick Change Mutagenesis Kit.  Primers were 
obtained from IDT Technologies (Coralville, IA) and were designed to target the 
DGG coding regions for specific residues (Table 1).  Primers were then amplified 
through PCR with PfuUltra High-Fidelity DNA Polymerase (Strategene).  To 
destroy dam-methylated template DNA, PCR products were incubated with Dpn I 
restriction enzyme. 2 µl of each digested PCR reaction was used to transform 45 
µl of XL10-Gold ultracompetent E. coli cells (Strategene).  Standard Luria Broth 
Agar plates containing 100 µg/ml ampicillin were then streaked with each 
transformation and clones were sequenced by the UIUC Core Sequencing 
Facility (Urbana, IL) to ensure expected mutations.  Once desired mutations were 
confirmed, one clone taken from each reaction was used to transform competent 
BL21(DE3) E. coli cells (Stratagene) and generate large quantities of the mutant 
enzyme.  The final mutations generated were Asp26Ala, Gly27Ser and Gly28Ser. 
 
 
 
 
 23 
 
 
Table 1 Primers Used for Site-Directed Mutagenesis of Asp26, Gly27 and Gly28.  Lowercase 
letters are the wild type sequence, capital letters are introduced mutations and bold letters 
indicate the target codon. 
. 
 
BHMT Purification Procedure 
 
 The pTYB4::hBHMT vectors containing the wild type or mutant coding 
sequence were transformed into BL21(DE3) competent cells.  A colony of cells 
was added to 30 ml 2XYT broth containing 100 µg/ml ampicillin and incubated at 
37ºC, 250 rpm overnight.  The culture was then centrifuged and the pellet was 
resuspended in 1 ml 2XYT broth.  The resuspended cells were then added to a 1 
L flask of 2XYT broth containing 100 µg/ml ampicillin and 250 µM ZnCl2 and were 
allowed to grow at 37ºC, 180 rpm.  When the OD600 reached 1.0, IPTG 
(Research Products International, Mt. Prospect, IL) was added to a final 
concentration of 1 mM and the flask was incubated overnight at 20ºC, 180 rpm.  
The culture was centrifuged and the collected cells were French pressed at 1500 
p.s.i. and sonicated on ice 5 times for 1 minute at 30% output with a Branson 
Mutation 5’-----------------------------------------------------------------------3’ 
Asp26Ala ggagagattgtgattggCgcCggagggtttgtctttgcactgg 
Gly27Ser ggagagattgtgattggagaCTCGgggtttgtctttgcactgg 
Gly28Ser gagagattgtgattggagatggaTCCtttgtctttgcactggag 
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Digital Sonifier 450 (Branson Ultrasonics Corporation, Danbury, CT).  The cell 
lysate was centrifuged and the supernatant was obtained for chitin-affinity 
chromatography.  The supernatant was run slowly over a 10 ml chitin bead 
column (New England Biolabs) allowing the C-terminus fused intein-chitin-
binding domain tag of recombinant BHMT to bind tightly to chitin.  The column 
was then washed with 500 ml of column buffer (20 mM TrisHCl pH 8.0, 0.1 mM 
EDTA, 0.1% Triton X100, 500 mM NaCl).  The on-column cleavage of the 
enzyme from its intein-chitin-binding domain tag occured with the addition of the 
thiol reagent β-mercaptoethanol (βME) in buffer.  Elution of the protein from the 
chitin column followed overnight incubation in cleavage buffer (20 mM TrisHCl 
pH 8.0, 0.1 mM EDTA, 50 mM NaCl, 0.5% βME).  Eluted enzyme was stored in 
cleavage buffer with 10% glycerol at -80ºC.  Protein purity was analyzed by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 
combination with Coomassie Brilliant Blue staining and protein concentrations 
were determined by a Coomassie dye-binding assay (BioRad) using bovine 
serum albumin as standard.  A wild type control enzyme was tested in each 
assay and the same preparation was used for each mutant. 
 
In Vitro Assay for BHMT Activity 
 
 Purified enzyme was incubated at 37ºC for one hour in the presence of 50 
mM TrisHCl pH 7.5, 0.025% bovine serum albumin, 0.07% βME, 2 mM 
radiolabeled glycine betaine (0.1 µCi) (Moravek, Brea, CA) and 5 mM D,L-
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homocysteine.  D,L-homocysteine was freshly prepared by dissolving 15.4 mg of 
D,L-homocysteine thiolactone in 400 µl of 2N NaOH.  The solution was incubated 
at room temperature for 5 minutes then neutralized with 600 µl saturated 
KPO4H2.  The sample enzyme volume was chosen such that the reaction 
consumed less than 5% of the substrates during incubation and catalysis.  
Following incubation, 2.5 ml of ice water was added to the assay to stop the 
reaction.  The solution was then loaded onto a ion-exchange column containing 1 
ml of Dowex 1x4 to bind the radiolabeled end products, methionine and DMG.  
The column was washed with water (3 X 5 ml) then eluted into scintillation vials 
with 3 ml of 1.5 N HCl.  A blank vial which contains all the reaction components 
minus the enzyme sample was also incubated, loaded, washed and counted.  
Disintegrations per minute were measured for determination of BHMT activity 
with the blank value subtracted from the assay counts.  Each sample was 
assayed in duplicate to ensure accuracy. 
 
Circular Dichroism (CD) Spectropolarimetry 
 
 Mutant enzymes were assessed for gross morphological abnormalities 
using a Jasco J-715 Spectropolarimeter (Jasco, Easton, MD).  All enzymes were 
diluted to a final concentration of 2.5 µM in elution buffer so salt, reducing agent 
and pH content were similar between samples. 
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Inductively Coupled Plasma Spectrometry  (ICP) 
 
 Metal content was measured for each enzyme following two 6 hour 
dialyzes in 1 L of buffer (50 mM Tris-PO4 pH 7.5, 100 µM TCEP) at 4ºC to 
remove any excess chloride, which can cause strong interference with ICP 
measurements.  A sample of buffer was taken after dialysis and used as a blank 
measurement in attempt to prevent any other background interference.  K+ 
measurements were taken using inductively coupled plasma emission 
spectrometry (Perkin Elmer, Norwalk, CT) by the University of Illinois 
Microanalytical Laboratory (Urbana, IL). 
 
Initial Rate Betaine Kinetics (Km, Vmax) 
 
 Purified recombinant enzyme  (30-50 µg) was assayed in the presence of 
5 mM D, L-homocysteine, 0.25 mM radiolabeled glycine betaine (0.5 µCi) and a 
series of concentrations of unlabeled betaine (0-20 mM).  Collection and 
assessment of reaction products occurred as in the standard activity assay. 
 
Ligand Binding Assay Using Intrinsic Fluorescence 
 
 Purified enzyme (1 µM, 45 µg/ml) was prepared in a simple buffer (20 mM 
TrisHCl pH 7.5, 5 mM βME, filter sterilized).  The product DMG was added at a 
saturating level (1 mM) and the substrate Hcy was added incrementally.  Each 
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concentration was allowed to equilibrate before excitation at 295 nm and 
collection of a short intrinsic fluorescence emission spectrum from 295-350 nm.  
Spectra were measured on a Jobin Yvon Horiba FluoroMax-3 and visualized 
using FluoroMax-3 software (version 2.0).  Amplitude of emission at 338 nm was 
used to calculate the dissociation constants (Kd) for Hcy. 
 
 
Results and Discussion 
 
Dialysis for Removal of K+ 
 
Many attempts were made to remove the K+ ion from BHMT wild type 
enzyme.  Urea concentrations from 1-3 M were used in attempt to relax the 
BHMT structure in hopes it would release K+.  The standard activity assay was 
run on the dialyzed enzymes, making sure to avoid reintroduction of K+.  Since 
KPO4H2 is used in preparation of D,L-Hcy thiolactone for the assay, D,L-
homocystine dissolved in HCl, neutralized with Tris base and reduced with TCEP 
was used instead.  Activity remained constant before and after dialysis.  
Therefore, we assume that K+ is bound tightly in BHMT and cannot be removed 
through dialysis with urea alone. 
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Figure 3 SDS-PAGE of BHMT Wild Type and Asp26Ala, Gly27Ser and Gly28Ser Mutants.  
Protein was visualized by a Coomassie staining procedure and the gel image was captured using 
a Hewlett-Packard Scanjet 7400c (Hewlett-Packard, Palo Alto, CA).  All lanes were loaded with 
~2 µg total protein. 
 
 
Enzyme Purity and Activity 
 
 Purifications of wild type BHMT and K+ ligand mutants were judged to be 
homogenous after SDS-PAGE yielding a single band of 45 kD for all 4 enzymes 
(Fig 3).  The purification procedure consistently yielded varying concentrations of 
protein with each mutant; Gly27Ser always yielded the lowest concentration.  
WT 
↓ 
D26A 
↓ 
G27S 
↓ 
G28S 
↓ 
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Each one of the K+ ligand mutants exhibit reduced enzyme activity in the 
standard activity assay (Table 2).  The mutant that was least affected, Gly28Ser, 
had a 57% reduction in activity while Gly27Ser was almost inactivated completely 
with a 98% loss in activity.  However, the reduced activities of both mutants show 
that a substitution of the larger serine residue for glycine at either location has a 
dramatic effect on enzyme efficiency.  Altering the residue at position 26 to 
 
 
Table 2 Standard Activity Rates of BHMT WT and Asp26, Gly27 and Gly28 Substitutions.  
Protein concentrations determined by a Coomassie dye-binding assay (BioRad).  Other data 
determined by the standard assay for BHMT activity.  Experimental details described previously. 
 
 
alanine reduced activity by 81% and demonstrates the importance of a 
negatively-charged carboxyl group and side chain carboxy oxygen that is 
provided by aspartate.  The neutral methyl group of alanine at this position 
 
 
Enzyme 
Protein 
Concentration 
(mg/ml) 
14C 
DPM- 
10 µl 
 
Units/ml 
(nmol/hr/ml) 
 
Units/mg 
(nmol/hr/mg) 
 
Units/mg 
(relative) 
Wild Type 0.1674 1526 595.9 3559.7 100 
 
Asp26Ala 
 
1.3888 2220 942.3 678.5 19 
 
Gly27Ser 
 
0.1061 190 6.3 59.7 2 
 
Gly28Ser 
 
0.5198 2324 795.9 1531.2 43 
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greatly disables the enzyme, as hypothesized. Using such saturating levels of 
substrate in this assay usually has the ability to make up for any subtle defects 
there may be in substrate binding but such dramatic decreases in activity indicate 
that these mutants are not functioning properly.  We conclude from the standard 
activity assay results that Asp26, Gly27 and Gly28 are important for BHMT 
activity and a weakened or irregular relationship with K+ may be responsible for 
some of these changes in activity. 
 
Enzyme Morphology 
 
 It is possible, though unlikely, that residue mutations in the DGG 
fingerprint of BHMT could affect general protein folding and structure.  CD 
Spectropolarimetry was used to check for any changes in gross morphology of 
the mutant proteins.  All three mutants retain the characteristic CD spectra found 
of wild type BHMT (Fig 4), all of which demonstrates a structure dominated by 
alpha-helices.  Therefore, the changes in activity or substrate binding that are 
observed in the DGG mutants are not consequences of drastic changes in 
protein secondary structure. 
 
Initial Rate Kinetics 
 
 Initial rate kinetics assays using varying concentrations of betaine were 
used to measure each mutant’s rate constant (Km) and specific activity (Kcat). 
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Since BHMT follows an ordered bi-bi mechanism of catalysis, Hcy is the first 
substrate bound followed by betaine.  It has been suggested that the 
conformational change induced by Hcy would be expected to facilitate assembly 
of the betaine-binding site, as betaine shows no affinity for BHMT without Hcy-
binding.  Any alterations in K+ binding that cause disruptions in Hcy-binding 
would result in decreased betaine-binding as well.  The differences observed in 
Km values between mutants and wild type enzyme (Fig 5) are less pronounced 
than those that will be shown in the steady-state kinetics experiments.  However, 
the Kcat values give a comparative view of the velocity per milligram of each 
enzyme in saturating levels of both substrates.  None of the three mutants were 
able to perform at the wild type level of specific activity.  Two mutants, Asp26Ala 
and Gly28Ser, had Kcat values around 50% of the wild type while Gly27Ser 
showed very low catalytic efficiency at only 15%.  These results illustrate a 
disruption in betaine-binding in the BHMT mutants.  Without altering residues in 
the betaine-binding domain and with gross structure intact, the decreased 
catalytic efficiency of these mutants can be a result of lower affinity of the 
enzymes to first bind Hcy.  To determine the effects of these mutations on Hcy-
binding specifically, we decided to use intrinsic fluorescence.   
 
Ligand Binding Kinetics 
 
 Defects within the K+ binding residues may affect the ability of BHMT to 
catalyze its reaction by disrupting the enzyme’s interaction with Hcy, as 
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suggested by the crystal structure.  Although the substrate binding sites remain 
structurally intact and unaltered, the rate of substrate association may be 
affected by the mutated interactions with K+.  Using the standard activity assay, 
substrates are provided at saturating (2.5 mM D,L-Hcy) or half-saturating (2 mM 
betaine) concentrations which have the ability to make up for subtle defects in 
substrate binding kinetics.  Dissociation constants (Kd), however, are measured 
under sub-saturating and saturating conditions which require the enzyme to 
come to equilibrium with the substrate concentration.  In these conditions, the 
rate of substrate binding equals the rate of substrate dissociation and can be 
measured in BHMT through changes in intrinsic tryptophan fluorescence (IF).  
BHMT contains seven tryptophan residues that, upon excitation, fluoresce and 
shifts in these residues due to ligand binding can be monitored through changes 
in the fluorescence emission spectrum.  Changes in steady-state IF intensity 
when one the product, DMG, was held constant at saturating levels while Hcy 
was varied were used to calculate the ternary Kds of Hcy for the three mutants.  
DMG is a potent inhibitor of BHMT and does so by binding to the betaine-binding 
site with high affinity and forming an abortive BHMT-Hcy-DMG complex.  It has 
been shown by Castro et al that changes in IF intensity of BHMT when saturated 
with DMG (1 mM) is dependent on the concentration of Hcy as DMG, like 
betaine, has no affinity for the enzyme without bound Hcy47.   BHMT, in the 
absence of ligands, has a fluorescence emission spectrum that displays a 
maximum value of 334 nm.  Fluorescence emission spectrums from 295-350 nm  
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were completed for each enzyme under constant saturating DMG levels and 
varying concentrations of Hcy.   
Kd values for wild type, Asp26Ala, Gly27Ser and Gly28Ser were calculated 
for Hcy using the changes in the fluorescence emission maximum at 338 nm 
following exposure to changing concentrations of Hcy.  Kd values reflect trends  
 
 
Enzyme Kd Value for D,L-Hcy (µM) 
Wild Type 4 
Asp26Ala 116 
Gly27Ser ***** 
Gly28Ser 61 
 
Table 3 Hcy Dissociation Constants for BHMT WT and Asp26, Gly27 and Gly28 
Substitutions.  ***** Binding not detected. 
 
 
observed in the standard activity assay (Table 3).  All mutants displayed less 
activity and have much larger Kd values for Hcy.  The assay does not detect any 
Hcy binding in the Gly27Ser mutant, even at concentrations that would saturate 
other mutants.  Of the two mutant enzymes that do bind Hcy, Asp26Ala is the 
most defective.  Because all substitutions showed decreased ability to bind Hcy 
and poor catalytic efficiency in the initial rate betaine kinetics, we can suggest 
that these defects cause disorder in both substrate binding sites. 
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The Gly27Ser substitution affects substrate binding/dissociation more 
dramatically than substitutions at positions 26 and 28.  However, all mutations of 
the DGG motif clearly affect steady-state Hcy-binding kinetics but changes in Kd 
alone cannot account for poor performace in the standard activity assay when all 
mutants would be saturated with Hcy and betaine.  Therefore, the catalytic 
turnover of the enzymes themselves must be affected somehow by these 
substitutions. 
 
ICP  
 
Our activity and steady-state kinetics data show that mutations within the 
DGG motif affect Hcy-binding and BHMT catalytic function.  We presume that the 
cause of these functional abnormalities stems from changes in the electrostatic 
charge around the K+ ion or the complete loss of K+ binding altogether.  
Therefore, we wanted to measure the amount of K+ in each enzyme to see if 
Hcy-binding and/or catalysis correlates to enzymatic K+ content. 
K+ metal concentrations were to be determined by the University of Illinois 
Microanalytical Laboratory.  To test the sensitivity of their apparatus, we first sent 
over wild type and Gly27Ser enzymes for K+ quantification.  Each enzyme binds 
one K+ ion and therefore we expected to find the nmoles of enzyme and K+ to be 
equal.  Our theoretical K+ concentrations were 2 nmoles/ml and 1 nmoles/ml for 
wild type and Gly27Ser respectively.  The Microanalytical Laboratory reported 
back with K+ concentrations of 3 nmoles/ml (wild type) and 0.28 nmoles/ml 
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(Gly27Ser).  Although these results were hopeful, many other attempts were 
made for all 4 enzymes to be quantified for K+ but the lab was unable to 
reproduce the initial results.  Due to the sensitivity and variability of measuring K+ 
with ICP and the high enzyme concentrations the machines require, we were 
forced to abandon this procedure.  Another method of quantifying K+ in BHMT 
will need to be examined in the future.  
 
 
Conclusion 
 
 These data support our hypothesis that Asp26, Gly27 and Gly28 are 
important residues in BHMT function.  All three residues directly make a 
substantial contribution to Hcy-binding, enzyme velocity and catalytic efficiency.  
Although Gly28 was not named as a residue directly involved with the interaction 
with K+, we chose to look at it as the third piece in the DGG motif.  Over the 
course of the work here, the Gly28Ser mutant consistently outperformed the 
other two mutants.  This leads to the idea that changes in the K+ coordination 
sphere may prove to be more detrimental to BHMT function than changes to this 
other conserved residue.  Whether Asp26 or Gly27 mutations caused 
substitution-induced structural, electrochemical or both types of changes within 
the K+ binding sphere will need to be examined closely in the future.  Though we 
cannot fully correlate the poor enzymatic performances to a loss in K+, we have 
begun to get an idea that K+ may prove to be vital for BHMT function.  A more 
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sensitive K+ quantification design, through ICP or the use of radiolabeled K+ 
isotopes, will be necessary to determine when, if ever, BHMT releases the ion.  
Once this happens, we will gain more insight into the role of K+ in BHMT catalysis 
and bring us to the next step in BHMT research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
References 
(1) Finkelstein, J.D.; Kyle, W.E.; Harris, B.J.  Arch Biochem Biophys 1971, 
146, 84-92. 
(2) Finkelstein, J.D.; Harris, B.J.; Kyle, W.E.  Arch Biochem Biophys 1974, 
165, 774-779. 
(3) Keating, J.N.; Weir, D.G.; Scott, J.M.  Clin Sci 1985, 69, 287-292. 
(4) Xue, G.P.; Shoswell, A.M.  Comp Biochem Physiol 1985, 80B, 489-494. 
(5) Smith, A.E.; Matthews, R.G.  Biochemistry 2000, 39, 13880-13890. 
(6) Avila, M.A.; Berasain, C.; Prieto, J.; Mato, J.M.; Garcia-Trevijano, E.R.; 
Corrales, F.J.  Curr Med Chem Cardiovasc Hematol Agents 2005, 3, 267-
281. 
(7) Finkelstein, J.D.; Martin, J.J.  J Biol Chem 1984, 259, 9508-9513. 
(8) McKeever, M.P.; Weir, D.G.; Molloy, A.; Scott, J.M.  Clin Sci 1991, 81, 
551-556. 
(9) Slow, S.; Donaggio, M.; Cressey, P.J.; Lever, M.; George, P.M.; 
Chambers, S.T.  Journal of Food Composition and Analysis 2005, 18, 
473-485. 
(10) Zwart, F.J.; Slow, S.; Payne, R.J.; Lever, M.; George, P.M.; Gerrard, J.A.; 
Chambers, S.T.  Food Chemistry 2003, 83, 197-204. 
(11) Brosnan, J.T.; Jacobs, R.L.; Stead, L.M.; Brosnan, M.E.  Acta Biochim Pol 
2004, 51, 405-413. 
(12) World Health Organization.  Causes of Death 2004.  2004, assessed 2009 
<http://www.who.int/research/en/>. 
 41 
(13) McCully, K.S.; Wilson, R.B.  Atherosclerosis 1975, 22, 215-227. 
(14) Kanwar, Y.S.; Manaligod, J.R.; Wong, P.W.K.  Pediatric Res 1976, 10, 
598-609. 
(15) Zemen, F.J. Clinical Nutrition and Dietetics 1991, New York: Macmillan 
Publishing Company. 
(16) Motulsky, A.G.  American Journal of Human Genetics 1996, 58, 17-20. 
(17) Selhub, J.; Jacques, P.F.; Wilson, P.W.F.; Rush, D.; Rosenberg, I.H.  
Journal of the American Medical Assoc 1993, 270, 2693-2698. 
(18) Rimm, E.B.; Willet, W.C.; Hu, F.B.; Sampson, L.; Colditz, G.A.; Manson, 
J.E.; Hennekens, C.; Stampfer, M.J.  Journal of the American Medical 
Assoc 1998, 279, 359-364. 
(19) Kang, S.; Wong, P.W.K.; Malinow, M.R.  Annu Rev Nutri 1992, 12, 279-
298. 
(20) Ueland, P.M.; Refsum, H.; Brattstrom, L.  Atherosclerotic Cardio-Vascular 
Disease, Hemostasis, and Endothelial Function 1992, New York: Marcel 
Dekker, Incorporated. 
(21) Setoue, M.; Ohuchis, S.; Morita, T.; Sugiyama, K.  J Nutr Sci Vitaminol 
(Tokyo) 2008, 54, 483-490. 
(22) Schwahn, B.C.; Laryea, M.D.; Chen, Z.; Melnyk, S.; Pogribny, I.; Garrow, 
T.; James, S.J.; Rozen, R.  Biochem J 2004, 382, 831-840. 
(23) Schwahn, B.C.; Chen, Z.; Laryea, M.D.; Wendel, U.; Lussier-Cacan, S.; 
Genest, J. Jr.; Mar, M.H.; Zeisel, S.H.; Castro, C.; Garrow, T.; Rozen, R.  
Faseb J 2003, 17, 512-514. 
 42 
(24) Chen, Z.; Schwahn, B.C.; Wu, Q.; He, X.; Rozen, R.  Int J Dev Neurosci 
2005, 23, 465-474. 
(25) Venta, R.; Cruz, E.; Valcercel, G.; Terrados, N.  Med Sci Sports Exerc 
2009, 41, 1645-1651. 
(26) de Andrade, C.R.; Leite, P.F.; Montezano, A.C.; Casolari, D.A.; Yogi, A.; 
Tostes, R.C.; Haddad, R.; Eberlin, M.N.; Laurindo, F.R.; de Souza, H.P.; 
Corrêa, F.M.; de Oliverira, A.M.  Br J Pharmacol 2009, 157, 568-580. 
(27) Lin, C.P.; Chen, Y.H.; Leu, H.B.; Lin, S.J.; Chen, Y.L.; Huang, S.L.; Chen, 
J.W.  Front Biosci 2009, 14, 3836-3845. 
(28) Matté, C.; Stefanello, F.M.; Mackedanz, V.; Pederzolli, C.D.; Lamers, M.L.; 
Dutra-Filho, C.S.; Dos Santos, M.F.; Wyse, A.T.  Int J Dev Neurosci 2009, 
27, 337-344. 
(29) Namekata, K.; Enokido, Y.; Ishii, I.; Harada, T.; Kimura, H.  J Biol Chem 
2004, 279, 52961-52969. 
(30) Gupta, S.; Kϋhnisch, J.; Mustafa, A.; Lhotak, S.; Schlachterman, A.; 
Slifḱer, M.J.; Klein-Szanto, A.; High, K.A.; Austin, R.C.; Kruger, W.D.  
FASEB J 2009, 23, 883-893. 
(31) Herrmann, M.; Tami, A.; Wildemann, B.; Wolny, M.; Wagner, A.; Schorr, 
H.; Taban-Shomal, O.; Umanskaya, N.; Ross, S.; Garcia, P.; Hϋbner, U.; 
Herrmann, W.  Bone 2009, 44, 467-475. 
(32) Bozkurt, N.; Erdem, M.; Yilmaz, E.; Erdem, A.; Biri, A.; Kubatova, A.; 
Bozkurt, M.  Arch Gynecol Obstet 2009, 280, 381-387. 
 
 43 
(33) Herrmann, M.; Wildemann, B.; Claes, L.; Klohs, S.; Ohnmacht, M.; Taban 
Shomal, O.; Hϋbner, U.; Pexa, A.; Umanskaya, N.; Herrmann, W.  Clin 
Chem 2007, 53, 1455-1461. 
(34) Karakula, H.; Opolska, A.; Kowal, A.; Domański, M.; Ptotka, A.; Perzyński, 
J.  Pol Merkur Lekarski 2009, 26, 136-141. 
(35) Balinska, M.; Paszewski, A.  Biochem Biophys Res Commun 1979, 91, 
1095-1100. 
(36) Waditee, R.; Incharoensakdi, A.  Curr Microbiol 2001, 43, 107-111. 
(37) Mato, J.M.; Alvarez, L.; Ortiz, P.; Pajares, M.A.  Pharmacol Ther 1987, 73, 
265-280. 
(38) Jacobs, R.L.; House, J.D.; Brosnan, M.E.; Brosnan, J.T.  Diabetes 1998, 
47, 1967-1970. 
(39) Garrow, T.A.  J Biol Chem 1996, 271, 22831-22838. 
(40) Yamashita, T.; Hashimoto, S.; Kaneko, S.; Nagai, S.; Toyoda, N.; Suzuki, 
T.; Kobayashi, K.; Matsushima, K.  Biochem Biophys Res Commun 2000, 
269, 110-116. 
(41) Martin, J.J.; Finkelstein, J.D.  Anal Biochem 1981, 111, 72-76. 
(42) Garcia-Pérez, A.; Burg, M.B.  Physiol Rev 1991, 71, 1081-1115. 
(43) Sunden, S.L.; Renduchintala, M.S.; Park, E.I.; Miklasz, S.D.; Garrow, T.A.  
Arch Biochem Biophys 1997, 345, 171-174. 
(44) Szegedi, S.S.; Garrow, T.A.  Arch Biochem Biophys 2004, 426, 32-42. 
(45) Breksa, A.P., 3rd; Garrow, T.A.  Biochemistry 1999, 38, 13991-13998. 
 44 
(46) González, B.; Pajares, M.A.; Martìnez-Ripoll, M.; Blundell, T.L.; Sanz-
Aparicio, J.  J Mol Biol 2004, 338, 771-782. 
(47) Castro, C.; Gratson, A.A.; Evans, J.C.; Jiracek, J.; Collinsova, M.; Ludwig, 
M.L.; Garrow, T.A.  Biochemistry 2004, 43, 5341-5351. 
(48) Evans, J.C.; Huddler, D.P.; Jiracek, J.; Castro, C.; Millian, N.S.; Garrow, 
T.A.; Ludwig, M.L.  Structure 2002, 10, 1159-1171. 
(49) Skiba, W.E.; Taylor, M.P.; Wells, M.S.; Mangum, J.H.; Awad, W.M. Jr.  J 
Biol Chem 1982, 257, 14944-14948. 
(50) Park, E.I.; Renduchintala, M.S.; Garrow, T.  J Nutritional Biochemistry 
1997, 8, 541-545. 
(51) Emmert, J.L.; Garrow, T.A.; Baker, D.H.  J Nutr 1996, 126, 2050-2058. 
(52) Finkelstein, J.D.; Harris, B.J.; Martin, J.J.; Kyle, W.E.  Biochem Biophys 
Res Commun 1982, 108, 344-348. 
(53) Holm, P.I.; Bleie, O.; Ueland, P.M.; Lien, E.A.; Refsum, H.; Nordrenaug, 
J.E.; Nygard, O.  Arterioscler Thromb Vasc Biol 2004, 24, 301-307. 
(54) Holm, P.I.; Ueland, P.M.; Vollset, S.E.; Midttun, O.; Blom, H.J.; Keijzer, 
M.B.; den Heijer, M.  Arterioscler Thromb Vasc Biol 2005, 25, 379-385. 
 
 
 
 
 
 
